Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05248230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

4D-710 in Adult Patients With Cystic Fibrosis

Study acronym: CF
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 20 sitesv20
  2. Enrollment target: 40 to 30 Study sites: 19 to 20 · Primary completion date: Dec 2026 to Jun 2027 · Completion date: Jan 2030 to Jun 2031 · 2 morev19 Show 5 more changesShow less
    • Study sites: 19 to 20
    • Primary completion date: Dec 2026 to Jun 2027
    • Completion date: Jan 2030 to Jun 2031
    • Eligibility criteria expanded, about 36 words
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Phase: Phase 1/2 to Phase 2v18
  4. Site contacts updated at 3 of 19 sitesv17
  5. Study sites: 18 to 19v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 17 to 18v15
  2. Study sites: 16 to 17v14
  3. Site details revised at 15 of 16 sitesv13
  4. Enrollment target: 24 to 40 Study sites: 14 to 16 · Completion date: Jan 2027 to Jan 2030 · Eligibility criteria expanded, about 99 words · 2 morev12 Show 5 more changesShow less
    • Study sites: 14 to 16
    • Completion date: Jan 2027 to Jan 2030
    • Eligibility criteria expanded, about 99 words
    • Study description expanded, about 25 words
    • Study arms: 5 to 3

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Aug 2024 to Dec 2026 Enrollment target: 21 to 24 · Study sites: 13 to 14 · Completion date: Aug 2025 to Jan 2027 · 3 morev11 Show 6 more changesShow less
    • Enrollment target: 21 to 24
    • Study sites: 13 to 14
    • Completion date: Aug 2025 to Jan 2027
    • Eligibility criteria expanded, about 6 words
    • Study description revised
    • Study arms: 3 to 5

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 12 to 13v10
  7. Study sites: 11 to 12v9
  8. Study sites: 9 to 11v8
  9. Eligibility criteria expanded, about 29 wordsv7 See this version in full on ClinicalTrials.gov ↗
  10. Study sites: 8 to 9v6
  11. Study sites: 6 to 8v5
  12. Study sites: 4 to 6 Eligibility criteria shortened, about 14 wordsv4 Show 1 more changeShow less
    • Eligibility criteria shortened, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites: 2 to 4v3
  14. Primary endpoint revised Study sites: 1 to 2 · Start date changed from estimate of Feb 2022 to Mar 29, 2022 · Eligibility criteria expanded, about 57 words · 1 morev2 Show 4 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Feb 2022 to Mar 29, 2022
    • Eligibility criteria expanded, about 57 words
    • Study title shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
Trial Details
NCT Number NCT05248230
Lead Sponsor 4D Molecular Therapeutics
Conditions Cystic Fibrosis Lung
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov